Niagen Bioscience
NAGE· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +19.9% in FY2025
Robert Fried is the CEO of Niagen Bioscience and was paid $8.4M in FY2025 (Dec), up 592%.
Pay$100 in the stock at the end of FY20 → $133
Executives3
See all- 1Robert FriedChief Executive OfficerFY2025
- 2Ozan PamirChief Financial OfficerFY2025
- 3Carlos LopezSVP, General CounselFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allNiagen Bioscience paid its 3 named executives $9.7M in total in FY2025 (Dec). CEO Robert Fried was paid $8.4M of that.
| Name | |||
|---|---|---|---|
| Robert FriedChief Executive Officer | |||
| Ozan PamirChief Financial Officer | Not disclosed | ||
| Carlos LopezSVP, General Counsel | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Niagen Bioscience. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board5
See all- Steven D. RubinLead independent director · 18 yr on the boardIndependentAudit, Compensation (Chair)—Paid as an executive
- Wendy YuDirector · 8 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
- Gary NgDirector · 4 yr on the boardIndependentCompensation—Paid as an executive
- Hamed ShahbaziDirector · 3 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
- Kristin PatrickDirector · 3 yr on the boardIndependentAudit, Nominating and Corporate Governance (Chair)—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 29, 2026 | FY2025 |
| Annual report | 10-K | Mar 4, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 29, 2025 | FY2024 |
| Annual report | 10-K | Mar 4, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 25, 2024 | FY2023 |
| Annual report | 10-K | Mar 6, 2024 | FY2023 |
